Haemonetics - HAE Stock Forecast, Price & News

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Haemonetics Trading Up 0.3 %

Shares of NYSE:HAE opened at $76.21 on Friday. Haemonetics has a 52 week low of $43.50 and a 52 week high of $77.22. The company's 50 day moving average is $66.83 and its two-hundred day moving average is $60.54. The company has a current ratio of 3.81, a quick ratio of 2.27 and a debt-to-equity ratio of 0.99. The company has a market cap of $3.91 billion, a PE ratio of 58.18 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Rating) last announced its quarterly earnings data on Wednesday, August 10th. The medical instruments supplier reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.51 by $0.07. The company had revenue of $261.50 million for the quarter, compared to the consensus estimate of $249.00 million. Haemonetics had a net margin of 6.60% and a return on equity of 18.62%. The company's quarterly revenue was up 14.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.50 EPS. Equities analysts predict that Haemonetics will post 2.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

HAE has been the subject of several research reports. Barrington Research upped their price objective on shares of Haemonetics from $77.00 to $88.00 and gave the company an "outperform" rating in a research note on Thursday, August 11th. StockNews.com upgraded shares of Haemonetics from a "hold" rating to a "buy" rating in a report on Thursday, July 21st. JMP Securities upped their target price on shares of Haemonetics from $80.00 to $90.00 and gave the stock a "market outperform" rating in a research note on Thursday, August 11th. Raymond James upped their target price on shares of Haemonetics from $76.00 to $88.00 and gave the stock an "outperform" rating in a research note on Thursday, August 11th. Finally, Citigroup upped their target price on shares of Haemonetics to $74.00 in a research note on Monday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $82.80.

Insider Activity at Haemonetics

In related news, Director Mark W. Kroll sold 8,016 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $73.71, for a total value of $590,859.36. Following the transaction, the director now directly owns 16,231 shares of the company's stock, valued at approximately $1,196,387.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Mark W. Kroll sold 8,016 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $73.71, for a total transaction of $590,859.36. Following the completion of the sale, the director now owns 16,231 shares in the company, valued at approximately $1,196,387.01. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Simon sold 1,148 shares of the stock in a transaction on Monday, June 13th. The stock was sold at an average price of $62.60, for a total transaction of $71,864.80. Following the sale, the chief executive officer now owns 213,724 shares of the company's stock, valued at approximately $13,379,122.40. The disclosure for this sale can be found here. Insiders have sold 10,002 shares of company stock valued at $715,374 in the last ninety days. Insiders own 1.65% of the company's stock.